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Introduction
• People with HIV infection are at least 50 times more likely to get
lymphoma as compared to the general population.

Discussion
CT scan reveals diffuse circumferential gastric wall
and omental thickening w splenomegaly

PET scan demonstrates high abdominal tumor
burden with distant lymph nodes

• 25-40% of these lymphomas will be Burkitt Lymphoma (BL) – an
aggressive B cell malignancy with a high proliferative rate and potentially
fatal within months if not diagnosed and treated in a timely manner.

• Lymphoma in the leading cause of cancer-related deaths among HIVinfected patients in the anti-retroviral therapy era.
• Burkitt lymphoma (BL) is a highly proliferative NHL deriving from B
cells and with characteristic oncogenic pathways, including
translocation in the MYC gene-- a gene that normally plays a role in
controlling cell proliferation, differentiation and apoptosis.

• This translates to a 10-20% individual life-time risk of BL for an HIV
infected person.

• The WHO classifies 3 different clinical variants of BL: endemic,
sporadic and immunodeficiency-associated.

• The incidence of BL declined after the introduction of highly active
antiretroviral therapy (HAART), but to a lesser extent than other HIVassociated malignancies.

• Unlike other HIV-associated lymphomas, BL is frequently noted in
patients with CD4 cell counts >200 and viral loads suppressed by ART

• Epidemiologic studies suggest the incidence of BL will increase as the HIVinfected population ages

• HIV-associated BL typically presents with extra-nodal disease, mostly
commonly the stomach
• Intra-abdominal BL may present with abdominal pain, nausea,
vomiting, GI bleeding, bowel obstruction; fever, night sweats, weight
loss (B symptoms), fatigue and malaise are also common.

Endoscopy shows a nonbleeding gastric ulcer>80
mm w/diffuse gastric inflammation

• Approximately 70% will present with wide spread disease (stage III or
IV), in addition to elevated LDH and uric acid levels

Case Presentation

• The classic “starry sky appearance” is not often seen in the
histological examination of HIV-associated BL. Most are positive for
Epstein Barr Virus (EBV).

A 24 yo woman with known HIV presented with 1 month of intermittent
fevers, chills, nausea and diffuse abdominal pain most notable in the
epigastric region. Her symptoms acutely worsened in the last week,
prompting her visit to the Emergency Department.

• Recent studies suggest the pathobiology of HIV-associated
lymphomas is distinct from non-HIV lymphomas. HIV may directly
induce B-cell activation. Further oncogenic viruses, as EBV, are more
prevalent in HIV-associated lymphomas.

***

• Survival with HIV-associated BL is approaching that of HIV-negative BL
thanks to the development of short duration, dose intensive
combination chemotherapy with aggressive CNS prophylaxis, the
availability of rituximab and the implementation of effective ART

Past Medical History:
• HIV- diagnosed in 2014. Last on ART Feb-May 2019 while in jail. CD4 count
596 (low at 26%) and HIV RNA viral count 26,400 prior to ART initiation.
CD4 count improved to 33% with an undetectable viral load in April.
• Chronic hepatitis C
• Active IVDU – heroin, methamphetamines
• Tobacco dependence
Exam:
• Vitals: HR 135, RR 22, Temp 102.8 F, normotensive,SpO2>95% on room air
• Profuse sweating, notably uncomfortable
• New 2/6 holosystolic heart murmur in LUSB with no radiation
• Left lower quadrant and epigastric tenderness, negative Murphy’s sign

Gastric biopsy demonstrates diffuse infiltration of large lymphoid cells with artifact.
(A) EBER slide reveals EBV positivity. (B) Test positive for CD20 confirms B-cell lineage.
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Take Home Points
• This case emphasizes the importance of considering lymphomas in
the HIV positive patient presenting with subacute abdominal
symptoms. CT abdomen pelvis with contrast, possibly endoscopy,
should be considered as part of the work up.

Labs on admission:
• Hgb 9 (baseline: 11)
• Normal complete metabolic panel
• HIV RNA viral load 55,800
• CD4 count 596, 32%
Hospital Course:
• Started on broad spectrum antibiotics for presumed endocarditis in the
setting of active IVDU
• TTE revealed no vegetations, blood cultures negative
• CT abdomen pelvis obtained the night of admission demonstrated diffuse
gastric thickening with evidence of omental seeding with nodularity and
splenomegaly
• Endoscopy completed the following
day found
a large nonbleeding gastric
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ulcer and diffuse gastric inflammation.
• Pathology of endoscopic biopsies of the gastric antrum identified Diffuse
Large B-cell Lymphoma (DLBCL) and H.pylori.
• Immunohistochemistry test positive for Epstein Barr Virus.
• The patient was started on Biktarvy (last use 1-3 months prior)
• PET scan was done for staging revealed advanced disease with a diffuse
tumor burden
• MYC rearrangement detected on FISH analysis, consistent with high grade
Burkitt lymphoma
• She completed 1 cycle of Short Course EPOCH-RR with a guarded
prognosis. There was high concern for TLS and gastric perforation due to
the extensive abdominal tumor burden. Fortunately, neither happened.
• Thus far, she has tolerated 3 of the anticipated 6 chemo cycles with
relatively minor complications by comparison including bradycardia,
frequent NSVT and neutropenia necessitating adjustments to her
chemotherapy regimen and schedule delays.
• Her pain control has remained a challenge in light of her ongoing IV
substance use.

• Rare cases of IRIS- associated Burkitt Lymphoma have been reported,
typically within 6 months after the initiation of HAART. It is unclear if
that was the case with our patient.

• HIV-associated BL, unlike other lymphomas, can develop in HIVpatients well controlled on ART
• BL is an aggressive malignancy that can be fatal within months if not
appropriately diagnosed and treated.
• The impact of HIV, oncogenic viruses and HAART on the lymphoma
microenvironment is still unclear

Incidence and Survival among HIV-infected cases with BL.

• IRIS associated BL appears to be rare.

Graphs adapted from Cancer Epidemiol Biomarkers Prev; 25(9) Sept 2016.
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